GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $8.18 Consensus Target Price from Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten ratings firms that are currently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $8.18.

A number of research firms have recently weighed in on GDRX. Barclays reduced their price target on shares of GoodRx from $10.00 to $6.00 and set an "overweight" rating on the stock in a research note on Monday, November 11th. Citigroup dropped their price target on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating for the company in a research note on Friday, January 10th. KeyCorp reduced their price target on GoodRx from $7.00 to $6.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th. Morgan Stanley lowered their price objective on GoodRx from $7.00 to $6.00 and set an "equal weight" rating for the company in a research report on Tuesday, December 17th. Finally, Mizuho assumed coverage on shares of GoodRx in a research report on Wednesday, December 4th. They set a "neutral" rating and a $5.00 target price for the company.

Institutional Trading of GoodRx

A number of hedge funds and other institutional investors have recently bought and sold shares of GDRX. National Bank of Canada FI boosted its holdings in GoodRx by 34.9% during the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock worth $39,000 after acquiring an additional 2,151 shares during the last quarter. EP Wealth Advisors LLC purchased a new stake in shares of GoodRx during the third quarter valued at approximately $73,000. RPO LLC purchased a new stake in shares of GoodRx during the fourth quarter valued at approximately $52,000. Versor Investments LP bought a new stake in GoodRx during the fourth quarter worth $54,000. Finally, Verus Capital Partners LLC bought a new stake in GoodRx in the fourth quarter worth about $55,000. Institutional investors own 63.77% of the company's stock.

Remove Ads

GoodRx Price Performance

Shares of NASDAQ:GDRX traded down $0.12 during midday trading on Friday, hitting $4.49. The stock had a trading volume of 2,091,184 shares, compared to its average volume of 1,422,634. The company's 50-day moving average price is $4.73 and its 200-day moving average price is $5.64. The company has a market capitalization of $1.72 billion, a P/E ratio of -149.67, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25. GoodRx has a fifty-two week low of $4.09 and a fifty-two week high of $9.26. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.